File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Absence of fatty liver is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection

TitleAbsence of fatty liver is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection
Authors
Issue Date2020
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting Digital Experience 2020, Boston, USA, 13-16 November 2020. In Hepatology, 2020, v. 72 n. Suppl. 1, p. 658A, abstract no. 1084 How to Cite?
AbstractIntroduction: Concomitant chronic hepatitis B infection (CHB) and non-alcoholic fatty liver disease (NAFLD) is common, but the implications of NAFLD on clinical outcomes of CHB, including hepatocellular carcinoma (HCC), are not well-investigated.   Methods: CHB patients [both treatment-naïve and treated with nucleos(t)ide analogues (NA)] were recruited for transient elastography assessment for liver stiffness, and controlled attenuation parameter (CAP), a non-invasive quantification of hepatic steatosis, and were prospectively followed up for development of HCC. Steatosis and severe steatosis were diagnosed by CAP ≥248 dB/m and ≥280 dB/m respectively, and advanced fibrosis/ cirrhosis was diagnosed by liver stiffness ≥9 kPa. Results: Among 2403 CHB patients (55.6% male, median age 55.6 years, 57.1% NA-treated, median ALT 26 U/L), 48 patients developed HCC during a median follow-up of 46.4 months. Multivariate analysis showed increased CAP to be inversely associated with HCC development (OR 0.994, 95%CI 0.988-0.999). The cumulative probability of HCC was 2.88%, 1.56% and 0.71%, respectively for patients with no steatosis, mild-to-moderate steatosis, and severe steatosis, respectively (p=0.01). Subgroup analysis among patients without advanced fibrosis/cirrhosis and NA-treated patients showed increased CAP remaining to be inversely associated with HCC (OR 0.991, 95%CI 0.983-0.999; and OR 0.993, 95%CI 0.987-0.999 respectively). The risk of HCC increased from 1.56% to 8.89% in patients without severe steatosis if advanced fibrosis/cirrhosis were present (p<0.001). Conclusion: Reduced hepatic steatosis was significantly associated with a higher risk of incident HCC in CHB patients. Routine CAP and liver stiffness measurements can be important for risk stratification, especially in on-treatment patients.
DescriptionPoster Presentation - no. 1084
Persistent Identifierhttp://hdl.handle.net/10722/300622
ISSN
2023 Impact Factor: 12.9
2023 SCImago Journal Rankings: 5.011

 

DC FieldValueLanguage
dc.contributor.authorMak, LY-
dc.contributor.authorHui, WHR-
dc.contributor.authorFung, JYY-
dc.contributor.authorLiu, F-
dc.contributor.authorWong, DKH-
dc.contributor.authorCheung, KSM-
dc.contributor.authorYuen, RMF-
dc.contributor.authorSeto, WKW-
dc.date.accessioned2021-06-18T14:54:37Z-
dc.date.available2021-06-18T14:54:37Z-
dc.date.issued2020-
dc.identifier.citationThe Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting Digital Experience 2020, Boston, USA, 13-16 November 2020. In Hepatology, 2020, v. 72 n. Suppl. 1, p. 658A, abstract no. 1084-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/300622-
dc.descriptionPoster Presentation - no. 1084-
dc.description.abstractIntroduction: Concomitant chronic hepatitis B infection (CHB) and non-alcoholic fatty liver disease (NAFLD) is common, but the implications of NAFLD on clinical outcomes of CHB, including hepatocellular carcinoma (HCC), are not well-investigated.   Methods: CHB patients [both treatment-naïve and treated with nucleos(t)ide analogues (NA)] were recruited for transient elastography assessment for liver stiffness, and controlled attenuation parameter (CAP), a non-invasive quantification of hepatic steatosis, and were prospectively followed up for development of HCC. Steatosis and severe steatosis were diagnosed by CAP ≥248 dB/m and ≥280 dB/m respectively, and advanced fibrosis/ cirrhosis was diagnosed by liver stiffness ≥9 kPa. Results: Among 2403 CHB patients (55.6% male, median age 55.6 years, 57.1% NA-treated, median ALT 26 U/L), 48 patients developed HCC during a median follow-up of 46.4 months. Multivariate analysis showed increased CAP to be inversely associated with HCC development (OR 0.994, 95%CI 0.988-0.999). The cumulative probability of HCC was 2.88%, 1.56% and 0.71%, respectively for patients with no steatosis, mild-to-moderate steatosis, and severe steatosis, respectively (p=0.01). Subgroup analysis among patients without advanced fibrosis/cirrhosis and NA-treated patients showed increased CAP remaining to be inversely associated with HCC (OR 0.991, 95%CI 0.983-0.999; and OR 0.993, 95%CI 0.987-0.999 respectively). The risk of HCC increased from 1.56% to 8.89% in patients without severe steatosis if advanced fibrosis/cirrhosis were present (p<0.001). Conclusion: Reduced hepatic steatosis was significantly associated with a higher risk of incident HCC in CHB patients. Routine CAP and liver stiffness measurements can be important for risk stratification, especially in on-treatment patients.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.relation.ispartofAmerican Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2020-
dc.titleAbsence of fatty liver is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection-
dc.typeConference_Paper-
dc.identifier.emailMak, LY: lungyi@hku.hk-
dc.identifier.emailHui, WHR: huirex@connect.hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailCheung, KSM: cks634@hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.authorityMak, LY=rp02668-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityCheung, KSM=rp02532-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.authoritySeto, WKW=rp01659-
dc.description.natureabstract-
dc.identifier.hkuros322886-
dc.identifier.hkuros326987-
dc.identifier.volume72-
dc.identifier.issueSuppl. 1-
dc.identifier.spage658A, abstract no. 1084-
dc.identifier.epage658A, abstract no. 1084-
dc.publisher.placeUnited States-
dc.identifier.partofdoi10.1002/hep.31579-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats